Samsung Biologics Moves Into Peptide Manufacturing
Samsung Biologics launched an all-cash tender offer for PolyPeptide Group at CHF 44.31 per share, implying an equity value of approximately CHF 1.46 billion. The transaction is strategically important because it adds specialized peptide…
